BioAtla Statistics
Share Statistics
BioAtla has 58.02M shares outstanding. The number of shares has increased by 21.38% in one year.
| Shares Outstanding | 58.02M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 20.05% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 46.83M |
| Failed to Deliver (FTD) Shares | 1.12K |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 3.95M, so 6.8% of the outstanding shares have been sold short.
| Short Interest | 3.95M |
| Short % of Shares Out | 6.8% |
| Short % of Float | 8.43% |
| Short Ratio (days to cover) | 4.65 |
Valuation Ratios
The PE ratio is -0.95 and the forward PE ratio is -1.49.
| PE Ratio | -0.95 |
| Forward PE | -1.49 |
| PS Ratio | 0 |
| Forward PS | 7.9 |
| PB Ratio | 1.66 |
| P/FCF Ratio | -1.13 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for BioAtla Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.11, with a Debt / Equity ratio of 0.
| Current Ratio | 4.11 |
| Quick Ratio | 4.11 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.75% and return on capital (ROIC) is -177.33%.
| Return on Equity (ROE) | -1.75% |
| Return on Assets (ROA) | -1.03% |
| Return on Capital (ROIC) | -177.33% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.90M |
| Employee Count | 65 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -71.85% in the last 52 weeks. The beta is 1.02, so BioAtla 's price volatility has been higher than the market average.
| Beta | 1.02 |
| 52-Week Price Change | -71.85% |
| 50-Day Moving Average | 1.53 |
| 200-Day Moving Average | 1.93 |
| Relative Strength Index (RSI) | 26.5 |
| Average Volume (20 Days) | 1.08M |
Income Statement
| Revenue | n/a |
| Gross Profit | -103.73M |
| Operating Income | -129.69M |
| Net Income | -123.46M |
| EBITDA | -122.24M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.58 |
Balance Sheet
The company has 111.47M in cash and 2.46M in debt, giving a net cash position of 109.01M.
| Cash & Cash Equivalents | 111.47M |
| Total Debt | 2.46M |
| Net Cash | 109.01M |
| Retained Earnings | -416.26M |
| Total Assets | 62.24M |
| Working Capital | 41.10M |
Cash Flow
In the last 12 months, operating cash flow was -104.02M and capital expenditures -98.00K, giving a free cash flow of -104.11M.
| Operating Cash Flow | -104.02M |
| Capital Expenditures | -98.00K |
| Free Cash Flow | -104.11M |
| FCF Per Share | -2.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BCAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -385.07% |
| FCF Yield | -267.8% |
Analyst Forecast
The average price target for BCAB is $5, which is 646.3% higher than the current price. The consensus rating is "Hold".
| Price Target | $5 |
| Price Target Difference | 646.3% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -13.73 |
| Piotroski F-Score | 3 |